LAXMIDENTL
Laxmi Dental share price & financials
- Price
- ₹223.74
- Market cap
- ₹1.1k Cr
- Sector
- Healthcare
- Calls analysed
- 7
Laxmi Dental Limited Q1 FY27
What went well
- Revenue of ₹74.7 crores, up 13.9% YoY, highest ever quarterly revenue.
- EBITDA grew 20.6% YoY to ₹14.4 crores, with margins improving to 19.2%.
- PAT increased 23.8% YoY to ₹10.3 crores, with margins at 13.8%.
What Laxmi Dental Limited does
Laxmi Dental designs, manufactures and exports dental products through a vertically integrated model spanning custom-made crowns and bridges (Laboratory Offerings), branded clear aligners and aligner-manufacturing inputs (Aligner Solutions, under Bizdent/Vedia), an in-house intraoral scanner brand (iScanPro), and pre-formed paediatric dental crowns via its Kids-e-Dental joint venture. It earns by supplying finished dental prosthetics and devices to a large network of dental clinics, laboratories and dentists in India and abroad, and by selling its own raw materials (thermoforming sheets, 3D-printing resins) and equipment to other manufacturers. The company also holds an equity stake in IDBG AI Dent, an associate engaged in AI-based dental diagnostics.
Segments
- Laboratory Offerings
- Aligner Solutions
- Scanner Sales
- Paediatric Dental Products
- Dental network reached
- 22,000+ dental clinics, dental companies and dentists
- Export presence
- 95+ countries
- Manufacturing plants
- 6 (3 in Mira Road, 2 in Boisar - both Maharashtra, 1 in Kochi, Kerala)
- Supporting facilities
- 5 (2 Mumbai, 1 Delhi, 1 Bengaluru, 1 Ahmedabad)
- Manufacturing + supporting facility area
- ~1,47,030 sq. ft. as of March 31, 2025
- Cities served
- 300+ cities
Guidance record · Q1 FY27
what the last two calls moved 12 tracked 3 delivered 3 missed 6 open- FY25 Revenue delivered said Q3 FY25 Promised: around INR240 crores Q1 FY27: Promise period concluded.
- Revenue Growth missed said Q1 FY26 Promised: full-year revenue growth mark of 20% to 25% in FY '26 Q1 FY27: Promise period concluded.
- EBITDA Margin on track said Q3 FY26 Promised: coming close to a margin of between 18% to 20% [next year] Q1 FY27: Management reinstated guidance, targeting 18-20% EBITDA margin for FY27. Q1 reported margin was 19.2%.
All 12 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 13.6%, net profit up 25.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 57 | 62 | 61 | 66 | 72 +26% | 66 +6% | 74 +21% | 75 +14% |
| EBITDA | 9 | 10 | 10 | 12 | 11 +22% | 7 −30% | 14 +40% | 14 +17% |
| Net profit | 6 | 5 | 4 | 8 | 9 +50% | 2 −60% | 10 +150% | 10 +25% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −35.7% 1Y
1Y: ₹315.25 on 10 Sept 2025 → ₹202.84. High ₹362.35 (16 Sept 2025), low ₹158.25 (30 Mar 2026).
How the price took the results
close before → close after
- Q1 FY27
- −5.0%
- 12 Aug
- Q4 FY26
- +20.0%
- 22 May
- Q3 FY26
- −9.2%
- 11 Feb
- Q2 FY26
- −5.1%
- 12 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue grew 15.8% a year over 1 year, FY25 to FY26. Operating margin narrowed to 15.8%.
| Year ending | FY25 | FY26 |
|---|---|---|
| Revenue | ₹240 Cr | ₹278 Cr |
| Operating profit | ₹43 Cr | ₹44 Cr |
| Operating margin | 17.9% | 15.8% |
| Interest | ₹5 Cr | ₹0 Cr |
| Depreciation | ₹14 Cr | ₹16 Cr |
| Net profit | ₹32 Cr | ₹29 Cr |
| Net margin | 13.3% | 10.4% |
| Cash from operations | ₹44 Cr | ₹-5 Cr |
| Free cash flow | ₹28 Cr | ₹-23 Cr |
| ROCE | 19.0% | 15.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹11 Cr | ₹11 Cr |
| Reserves | ₹33 Cr | ₹9 Cr | ₹6 Cr | ₹31 Cr | ₹218 Cr | ₹232 Cr |
| Borrowings | ₹39 Cr | ₹50 Cr | ₹50 Cr | ₹61 Cr | ₹9 Cr | ₹13 Cr |
| Other liabilities | ₹34 Cr | ₹43 Cr | ₹40 Cr | ₹46 Cr | ₹28 Cr | ₹38 Cr |
| Total liabilities | ₹106 Cr | ₹103 Cr | ₹97 Cr | ₹139 Cr | ₹266 Cr | ₹294 Cr |
| Fixed assets | ₹42 Cr | ₹40 Cr | ₹40 Cr | ₹46 Cr | ₹51 Cr | ₹63 Cr |
| Capital work in progress | ₹7 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹2 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹6 Cr | ₹15 Cr | ₹27 Cr |
| Other assets | ₹56 Cr | ₹63 Cr | ₹56 Cr | ₹87 Cr | ₹199 Cr | ₹204 Cr |
| Total assets | ₹106 Cr | ₹103 Cr | ₹97 Cr | ₹139 Cr | ₹266 Cr | ₹294 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, the public added +6.82 pp while FIIs trimmed −3.49 pp. The shareholder count grew 32% to 36,937.
- Promoters
- 41.8%
- FIIs
- 30.1%
- DIIs
- 10.9%
- Public
- 17.2%
Since Jun 2025
- Public +6.82 pp
- FIIs −3.49 pp
- DIIs −3.41 pp
How it drifted, 6 quarters
Over this window the public went from 11.2% to 17.2% — +6.0 pp.
Ownership split by quarter, oldest first. Mar '25: Promoters 41.7%, FIIs 34.2%, DIIs 12.9%, Public 11.2%.Jun '25: Promoters 41.7%, FIIs 33.6%, DIIs 14.3%, Public 10.4%.Sep '25: Promoters 41.7%, FIIs 32.4%, DIIs 11.8%, Public 14.1%.Dec '25: Promoters 41.7%, FIIs 32.5%, DIIs 10.8%, Public 15.0%.Mar '26: Promoters 41.8%, FIIs 31.2%, DIIs 10.5%, Public 16.5%.Jun '26: Promoters 41.8%, FIIs 30.1%, DIIs 10.9%, Public 17.2%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- UTI-Healthcare Fund Mutual fund newly disclosed 1.09% held
The same filing shows 2 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Laxmi Dental Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Orbimed Asia Ii Mauritius Limited FPI fund | 22.41% | unchanged |
| Rajesh Vrajlal Khakhar | 16.95% | unchanged |
| Sameer Kamlesh Merchant | 15.83% | unchanged |
| Jigna Rajesh Khakhar | 7.84% | unchanged |
| ICICI Prudential Pharma Healthcare And Diaganostics (P.H.D) Fund Mutual fund | 4.68% | −0.31 pp |
| Goldman Sachs Funds - Goldman Sachs India Equity Portfolio Global fund house | 3.50% | unchanged |
| Amrish Desai | 2.02% | unchanged |
| Parag Jamnadas Bhimjiyani | 2.02% | unchanged |
| HDFC Mutual Fund - HDFC Pharma And Healthcare Fund Mutual fund | 1.37% | unchanged |
| Eastspring Investments - Asia Growth Opportunities Equity Fund Global fund house | 1.23% | −0.87 pp |
| Ashoka India Equity Investment Trust Plc FPI fund | 1.13% | unchanged |
| UTI-Healthcare Fund Mutual fund | 1.09% | newly disclosed |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Mutual funds in LAXMIDENTL
Filings to Jul 2026
0 new, 0 added, 0 trimmed, 0 sold out — net +0.00 L shares (+0.0%).
- Held by funds
- ₹14 Cr
- 1 schemes
- Biggest holder
- HDFC Pharma and Healthcare Fund
- ₹14 Cr · 0.5% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| HDFC Pharma and Healthcare Fund HDFC Mutual Fund | ₹14 Cr | held | Jan '25 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Jul 2026
0 added, 0 trimmed — net 0 shares (+0.0%)
- Funds are sitting on
- -52%
- vs est. average cost
- Held by funds
- ₹14 Cr
- 1 schemes · ≈ 1.3% of the company
Shares held by these funds +19%
Jan '25 6.44 L shares Jul '26
What the price assumes
Growth trapTo justify its price of ₹203, this stock must grow earnings at 24% every year for 7 years. Our analysis caps realistic growth at ~-9%. At that growth it is worth ₹34 — downside of 83%.
- Growth the price implies
- 24.0% a year
- for 7 years, fading to 4%
- It has actually compounded at
- -9.4% a year
- net profit, FY25–FY26
- The gap
- 0.3 pp
- -83% downside if it only repeats history
All earnings calls (7)
Read the Q1 FY27 call →Learn to analyse Laxmi Dental Limited
Guides on how to read this kind of business and the numbers that matter.